TERUMO CORPORATION Q1 FY2027 earnings call

• Overall Q1 Financial Performance

  • Achieved a record quarterly revenue of 311.8 billion yen, up 20% year-on-year nominally and 9% year-on-year on a local currency basis, supported by strong global demand especially in the Americas
  • Operating profit reached 89.5 billion yen, up 60% year-on-year; adjusted operating profit hit 79.6 billion yen, up 35% year-on-year
  • Profit growth came from core revenue expansion, plus 13 billion yen from a US tariff refund and 20 billion yen from one-time settlement proceeds; even excluding these temporary positive factors, Terumo delivered a record high quarterly profit
  • Pricing measures implemented across segments contributed positively to gross margin and profitability
  • R&D and SG&A expenses increased year-on-year in line with business expansion and continued investment in future growth-focused product development

• Regional Performance

  • Americas: All segments grew, with TIS, cardiovascular, hospital care solutions, and organ technologies all driving expansion, supported by strong broad demand
  • Europe: Stable growth from the neuro business, growth from pharmaceutical solutions, and double-digit revenue growth from global blood solutions
  • Japan: Growth led by the neuro and hospital care solutions segments
  • China: Solid performance from TIS and neuro, but TMCS performance was negatively impacted by slow overall market growth in the region
  • Asia (excluding China/Japan): Growth driven primarily by the TIS and cardiovascular segments

• CDMO Business Updates

  • Preparations for the Labor Custom investment plant (acquired last year) are progressing on schedule to begin operations in FY2027
  • The business continues to receive strong interest from US and European pharmaceutical companies, and is steadily building foundational capabilities for its global CDMO business

• Organ Technologies Business Updates

  • The organ preservation market utilizing normothermic machine perfusion (NMP) continues to expand
  • Terumo expects the business to outpace overall market growth going forward, backed by rising liver transplant volumes and an expanding global customer base

1. Cardiac and Vascular Company (CNV): Revenue grew 70% year-on-year on a local currency basis, with a 32% profit margin. The TIS segment was the top growth driver with strong broad-based demand especially in North America; the neuro business grew driven by Webb cerebral aneurysm treatment products across China, Japan, and Europe; the cardiovascular business performed well on solid global demand and pricing measures; the aerotech business saw a negative impact from a voluntary product recall, which was offset by strength in other categories to deliver overall revenue growth. CNV contributed 70% local currency revenue growth, the largest growth driver among Terumo's segments.

2. Medical Cell Care Solutions Company (TMCS): Delivered overall revenue and profit growth, with a 13% reported profit margin (16% excluding impacts from the acquired Labor Custom investment plant). Hospital care solutions grew on Japanese reimbursed price revisions and solid core product performance; pharmaceutical solutions grew driven by a rebound in domestic CDMO business and strong overseas sales of Plajack. TMCS contributed solid growth overall, with its two core business lines as main drivers.

3. Blood and Cell Technologies Company (TBCT): Global Blood Solutions grew on strong performance of blood collection products including Trema and the Revio automated blood processing system, plus growth from Plasma Innovations; Global Therapy Innovations delivered continued strong growth primarily in North America. TBCT achieved an 18% profit margin, supported by core product contributions, the US tariff refund, and improved core product profitability. Global Blood Solutions was one of the company's overall key growth drivers.

4. Pteromore Organ Technologies Business: Included in consolidated disclosures since Q3 of the prior fiscal year. Q1 revenue was 6.2 billion yen, up 39% year-on-year, maintaining high growth. A 15% Q1 profit margin was recorded due to one-time production system optimization costs for METRA, with the full-year 20% profit margin target unchanged. This business was also a key driver of overall Terumo's incremental growth in the quarter.

Terumo maintains its full-year FY2027 revenue guidance unchanged at 1.239 trillion yen, reflecting that the quarter's strong performance does not change the company's core top-line outlook. Only profit guidance is revised upward, to incorporate the one-time positive impacts of the 13 billion yen US tariff refund and 20 billion yen one-time settlement proceeds:

• Adjusted operating profit guidance is revised upward to 274.5 billion yen
• Operating profit guidance is revised upward to 257.5 billion yen
• The updated guidance implies a full-year adjusted operating margin of 22.2% and an operating margin of 20.8%
• Segment-level revenue guidance remains unchanged across all business units
• Upward profit revisions are concentrated in the CNV segment, which received the largest impact from the US tariff refund
• The 20% full-year profit margin target for the organ technologies business remains unchanged, despite one-time Q1 costs dragging down the quarterly margin
• Terumo still expects to achieve record full-year revenue and profit for FY2027, and remains on track to hit its GS26 strategic financial targets

The only disclosed operational risk in the transcript was a negative revenue impact on the CNV segment's aerotech business from the voluntary recall of certain Relay Pro thoracic stent graft system products. This impact was fully offset by strong performance from other aerotech product lines, so there was no material negative impact on the segment's overall revenue growth. No other material financial, operational, or market risks were discussed in this overview section of the earnings call.

There was no question and answer section included in the provided earnings call transcript excerpt.